Matthias Herz

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus
    Matthias Herz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clin Ther 24:73-86. 2002
  2. ncbi Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes
    M Herz
    Diabetes Product Team, El Lilly and Company, Indianapolis, Indiana, USA
    Curr Med Res Opin 18:188-93. 2002
  3. ncbi A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
    Matthias Herz
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Clin Ther 25:1074-95. 2003
  4. ncbi Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial
    Meng Tan
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Clin Ther 26:680-93. 2004
  5. ncbi Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes
    Imre Pavo
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46201, USA
    J Clin Endocrinol Metab 88:1637-45. 2003

Detail Information

Publications5

  1. ncbi Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus
    Matthias Herz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Clin Ther 24:73-86. 2002
    ..Humalog Mix75/25 (Mix75/25) is a novel premixed insulin containing 75% neutral protamine lispro (an intermediate-acting insulin) and 25% insulin lispro...
  2. ncbi Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes
    M Herz
    Diabetes Product Team, El Lilly and Company, Indianapolis, Indiana, USA
    Curr Med Res Opin 18:188-93. 2002
    ..To compare the plasma glucose (PG) response with a fixed mixture of 25% insulin lispro and 75% NPL (Mix25), prior to a meal and 3 h before exercise, to human insulin 30/70 (30/70) in patients with type 2 diabetes...
  3. ncbi A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
    Matthias Herz
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    Clin Ther 25:1074-95. 2003
    ....
  4. ncbi Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial
    Meng Tan
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Clin Ther 26:680-93. 2004
    ..Pioglitazone is a thiazolidinedione that reduces insulin resistance, and glimepiride is a sulfonylurea insulin secretagogue...
  5. ncbi Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes
    Imre Pavo
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46201, USA
    J Clin Endocrinol Metab 88:1637-45. 2003
    ....